‘My heart beats for animals’

2018 ◽  
Vol 183 (21) ◽  
pp. i-ii
Keyword(s):  
Clinical Practice ◽  
Young Scientist ◽  
Advisory Board ◽  
Cat Diseases

Italian vet Maria Flaminia Persichetti combined her PhD studies of vectorborne infections in cats with a job in clinical practice. Her research recently won her a young scientist award from the European Advisory Board on Cat Diseases.

Advisory board to offer guidance on clinical practice issues

2017 ◽  
Vol 27 (10) ◽  
pp. 6-6
Author(s):  
Valerie A. Canady
Keyword(s):  
Clinical Practice ◽  
Advisory Board

scholarly journals Improving Outcomes for Patients with Multiple Myeloma through the Optimization of Treatment Sequences

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3000-3000
Author(s):  
Maria Teresa Petrucci ◽  
João Mendes ◽  
Jennifer H. Boer ◽  
Gabriele Casamassima ◽  
Anna Willis ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Practice ◽  
Patient Outcomes ◽  
Full Range ◽  
Advisory Board ◽  
Health State ◽  
Attrition Rates ◽  
Total Survival ◽  
Wide Range ◽  
Treatment Sequences

Abstract Introduction: Multiple myeloma (MM) is an incurable disease characterized by the proliferation of malignant plasma cells within the bone marrow, causing a wide range of burdensome symptoms. Patients initiating treatment typically receive a combination of drugs across various classes with or without autologous stem cell transplantation (ASCT). However, patients will invariably relapse following initial treatment, and often require many lines of drug treatment over the course of their disease. Real-word data showed that a significant proportion of newly diagnosed MM patients that receive frontline (FL) treatment did not receive subsequent treatment. These high attrition rates suggest that using the best treatment upfront is crucial in delaying disease progression. The CASSIOPEIA (transplant-eligible [TE] setting), MAIA and ALCYONE (transplant-ineligible [TIE] setting) trials demonstrate that the addition of daratumumab (DARA) to standard of care treatments in FL significantly improves patient outcomes. Based on data from these trials, the European marketing authorization for DARA has been extended to the FL setting. To ensure the best possible long-term patient outcomes in clinical practice, the availability of new FL treatment options requires a redefinition of treatment patterns. Thus, we aim to investigate whether the adoption of DARA as a FL, as opposed to later-line, treatment of MM leads to better outcomes and improved clinical practice. Methods: In the absence of real-world sequencing data, we developed a clinical sequencing simulation using individual patient data from the DARA trials and indirect comparative evidence, across all indications in MM. We used progression-free survival curves to simulate health state transition probabilities across four lines of active treatment, to capture the efficacy of treatment sequences in MM. Patients start with initiation of FL treatment, and ASCT eligibility determines the sequences patients receive. Clinical expert opinion was sought to determine 1) the full range of meaningful treatment sequences and 2) which of these are used most in Italian clinical practice. Based on the clinical simulation outcomes, we calculated average time spent in each line of treatment, percentage of patients alive at different timepoints, and the total survival for patients initiating a sequence. This analysis included conservative attrition rates from trial data, 14% for TE (CASSIOPEIA) and 24% for TIE (MAIA/ALCYONE), assumed as similar across regimens in each setting. Results: In the TE setting, the best outcomes were achieved when using the DARA-based regimen (DVTd) as FL treatment, followed by either a LEN-based regimen (KRd) or a BOR-based regimen (PVd), resulting in a total survival of 14.2 and 14.1 years, respectively. In the TIE setting, the best outcomes were achieved when DRd or DVMP were used as FL treatment, followed by either a BOR-based regimen (PVd, for DRd) or a LEN-based regimen (KRd, for DVMP), resulting in a total survival of 11.7 and 10.9 years, respectively. In both the FL and second line (2L) settings, there was a clear survival benefit of using DARA. When comparing the DARA-based sequence with the current FL TE benchmark sequence (DVTd + KRd + Pd + Vd versus VTd + DRd + Kd + Pd), an additional survival of 1.5 years was observed in TE patients. When DARA was added to the current FL TIE benchmark sequence (DRd + PVd + Kd + Vd versus VMP + DRd + Kd + Pd), TIE patients lived on average 2.8 years longer. For TE patients, time spent progression-free ranged from an average of 4.83 to 7.99 years at FL, 1.42 to 5.40 years in 2L, 0.23 to 2.24 years in 3L and 0.17 to 1.53 years on 4L. For TIE patients, the variation was higher, leaving more room for optimization: 1.97 to 7.31 years at FL, 0.68 to 4.76 years in 2L, 0.17 to 3.25 years in 3L and 0.19 to 0.51 years in 4L. Conclusion: To our knowledge, this is the first sequencing simulation to consider optimal patient outcomes across several lines of MM treatment. The results show that the longest time in remission is achieved with the use of DARA-based regimens as FL treatment, significantly improving patient outcomes. Time spent progression free decreases with each subsequent line of treatment and the magnitude of the effect seen in the third and fourth treatment lines is not as significant as that of the effect seen in earlier treatment lines. Therefore, patients should be treated with the most effective treatment upfront. Disclosures Petrucci: Celgene: Honoraria, Other: Advisory Board; Janssen-Cilag: Honoraria, Other: Advisory Board; BMS: Honoraria, Other: Advisory Board; Takeda: Honoraria, Other: Advisory Board; Amgen: Honoraria, Other: Advisory Board; GSK: Honoraria, Other: Advisory Board; Karyopharm: Honoraria, Other: Advisory Board. Mendes: Janssen-Cilag Farmacêutica: Current Employment. Boer: Janssen: Consultancy. Casamassima: Janssen: Current Employment. Willis: Janssen: Consultancy. Wadlund: Janssen: Current Employment. Matthijsse: Janssen: Consultancy. Armeni: Astrazeneca: Consultancy; Boehringer Ingelheim: Consultancy; Novartis: Consultancy; Sanofi: Consultancy; Johnson & Johnson: Consultancy; Amgen: Consultancy; Janssen: Consultancy.

scholarly journals Review and update of the Health of the Nation Outcome Scales for Elderly People (HoNOS65+)

2018 ◽  
Vol 42 (6) ◽  
pp. 248-252
Author(s):  
Mick James ◽  
Bill Buckingham ◽  
Gary Cheung ◽  
Roderick McKay ◽  
Jon Painter ◽  
...  
Keyword(s):  
Older Adults ◽  
Clinical Practice ◽  
New Zealand ◽  
Elderly People ◽  
Interrater Reliability ◽  
Advisory Board ◽  
Clinical Implications ◽  
Clinician Training ◽  
Radical Revision ◽  
The Uk

Aims and methodThe Health of the Nation Outcome Scales for Elderly People (HoNOS65+) has been used widely for 20 years, but has not been updated to reflect contemporary clinical practice. The Royal College of Psychiatrists convened an advisory board, with expertise from the UK, Australia and New Zealand, to propose amendments. The aim was to improve rater experience when using the HoNOS65+ glossary by removing ambiguity and inconsistency, rather than a more radical revision.ResultsViews and experience from the countries involved were used to produce a series of amendments intended to improve intra- and interrater reliability and improve validity. This update will be called HoNOS Older Adults to reflect the changing nature of the population and services provided to meet their needs. These improvements are reported verbatim, together with the original HoNOS65+ to aid comparison.Clinical implicationsFormal examination of the psychometric properties of the revised measure is needed. However, clinician training will remain crucial.Declaration of interestNone.

scholarly journals The Scientific Advisory board resolution: Implementation of intermittently scanned Continuous Glucose monitoring in clinical practice to improve glycemic control

2021 ◽  
Vol 24 (2) ◽  
pp. 185-192
Author(s):  
V. A. Peterkova ◽  
A. S. Ametov ◽  
A. Y. Mayorov ◽  
G. R. Galstyan ◽  
D. N. Laptev ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Glycemic Control ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Data Interpretation ◽  
Advisory Board ◽  
Point Of View ◽  
Diabetic Patients ◽  
Scientific Advisory Board ◽  
Scientific Advisory

The Scientific Advisory Board chaired by Academician of the Russian Academy of Sciences, Peterkova V.A. was held 26 of November in Moscow to discuss the possibilities of continuous glucose monitoring technology (CGM) implementation into routine clinical practice in Russia in order to improve glycemic control in patients with diabetes mellitus (DM).The main aims for Advisory board were to determine the most significant indicators and parameters for CGM to be implemented in practice from a practical point of view of LMWH, necessary for implementation in clinical practice, for different patients groups with diabetes.The following questions and topics were raised within the discussion: the importance of additional indicators beyond glycated hemoglobin (HbA1c) for glycemic control assessment in diabetes patients, CGM positioning in International and Russian clinical guidelines, the accuracy of CGM devises and approaches to its assessment, the role of education programs for diabetic patients, including trainings in correct use and data interpretation and analysis of CGM data obtained, clinical evidence analysis for CGM in randomized trials and real world evidence.

scholarly journals Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board

Kardiologiia ◽  
2019 ◽  
Vol 59 (5S) ◽  
pp. 58-64
Author(s):  
N. M. Akhmedzhanov ◽  
N. N. Vezikova ◽  
M. I. Voevoda ◽  
A. S. Galyavich ◽  
V. S. Gurevich ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Clinical Practice ◽  
Ldl Cholesterol ◽  
Advisory Board ◽  
Lipid Lowering ◽  
Pcsk9 Inhibitors ◽  
Everyday Clinical Practice ◽  
Coronary Syndrome ◽  
Outcomes Study

On April 9, 2018, the national advisory board “Improvement of outcomes in patients with recent ACS: the place of PCSK9 inhibitors” was held in Moscow. Leading Russian experts in the field of atherosclerosis and lipid-lowering treatment attended the board. The purpose of the Board was to determine the place of PCSK9 inhibitors in the improvement of outcomes in patients with recent (less than 1 year) acute coronary syndrome (ACS). During the Board, three major aspects of lipid-lowering treatment were discussed: 1) issues in reaching the target levels of LDL cholesterol in real clinical practice among patients with recent ACS; 2) the results of ODYSSEY OUTCOMES study and their role in the improvement of outcomes in patients with recent ACS; 3) treatment with PCSK9 inhibitors in the management of patients with recent (less than 1 year) ACS in everyday clinical practice, the role of lipid centers.

scholarly journals Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5518-5518
Author(s):  
Emilia Scalzulli ◽  
Matteo Molica ◽  
Alunni Fegatelli Danilo ◽  
Lorenzo Rizzo ◽  
Roberto Latagliata ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Overall Survival ◽  
Clinical Practice ◽  
High Risk ◽  
Myelodysplastic Syndromes ◽  
Prognostic Score ◽  
Advisory Board ◽  
Transfusion Dependency ◽  
Very High ◽  
Bone Marrow Blasts

Abstract Background. 5-Azacitidine (5-AZA) had changed the therapeutic approach to intermediate-2/high IPSS risk myelodysplastic syndromes (MDS) improving the outcome of patients, even in the absence of a complete response. However, real-life experiences have reported contradicting results compared to the AZA001 randomized study. Aim of our analysis was to identify the clinico-biological features at baseline and during treatment associated with the overall survival (OS) and progression-free survival (PFS) at two years in a consecutive cohort of patients treated with hypometylating agent in the clinical practice. Moreover, we propose a new prognostic score for the identification of OS after the first four cycles of therapy. Patients and Method. We retrospectively analyzed a series of 110 MDS patients treated at a single institution with 5-AZA between September 2003 and January 2017. Patients were diagnosed according to the WHO 2016 criteria. 5-AZA was administered at a dose of 75 mg/m2 according to the 5+2+2 schedule every 28 days. Results. A male predominance was observed (male/female: 66%/34%) with a median age of 70 years (range 38-85). The median dose of 5-AZA received was 135 mg/day (range 105-150) after a median time from diagnosis of 2.3 months (range 0.1-119). Median duration of therapy was 9.5 cycles (range 1-77) with a median time on treatment of 8.5 months (range 1-86.7). OS of the whole cohort was 66.1% (CI 95% 57.2-76.4) at 1 year and 38.3% (CI 95% 29.4-49.9) at 2 years. Seventy-seven patients (70%) performed four cycles of therapy. According to the IWG criteria, 42 patients (54.5%) achieved a complete remission (CR), 11 (14.2%) a partial remission (PR), 17 (22.4%) maintained a stable disease (SD), 2 (2.5%) and 5 (6.4%) presented a progression disease (PD) and a failure, respectively. The 2-year OS was 68% in patients who obtained a CR/PR, 20% in patients with SD and 16% in patients with PD/failure (p<0.001). No differences in terms of OS were observed for gender (p=0.622) and age at baseline (<65years, 65-75 and >75 years, p=0.075). The baseline bone marrow blasts percentage did not impact on OS and PFS (OS, p=0.867; PFS, p=0.611). According to the Revised International Prognostic Score (R-IPSS), 22 (20%), 46 (42.8%) and 42 (38.2%) patients were classified as intermediate, high and very high-risk patients, respectively. We identified that the very high-risk group had an inferior 2-year OS (17%) compared to intermediate-group patients (64%, p<0.001). Indeed, we did not find significant difference according to the IPSS stratification (intermediate 42% vs high-risk 22%, p=0.253). Transfusion-independency at baseline was identified as a favorable prognostic factor on 1-year (66.8%) and 2-year OS (43.4%) compared to patients with transfusion dependency (36.4% and 22.2% if they required 1 unit/month or more than 1 unit at baseline at 2 years, p<0.001). After four cycles received, the persistence of bone marrow blasts >10% identified patients with a worse outcome, with a 2-year OS of 9.4% compared to 60.3% for patients with 0-5% blasts and 44.7% for patients with 5-10% blasts (p=0.002). The occurrence of one infection during the first four cycles impacted on the 2-year OS (31.6% vs 58.3% in patients without, p=0.032). We applied a dynamic prognostic score according to age, cytogenetic risk, transfusion need, number of 5-AZA cycles performed and type of response after the fourth cycle (Table 1): the combination of these variables identified 3 categories of risk with a significantly different 2-year OS: low-risk (72.3%), intermediate (19.8%) and high-risk (8.9%) (p<0.001, Fig. 1). Conclusions. Our results in a large and consecutive MDS cohort treated outside of clinical trials defined prognostic factors, such as transfusion dependency, persistence of >10% blasts after four cycles and absence of infections, capable of identifying patients with a good outcome. A prognostic score is proposed that requires independent validations in similar cohorts of patients. Disclosures Rizzo: Sapienza University, Rome: Other: Resident in Hematology. Foà:NOVARTIS: Speakers Bureau; CELTRION: Other: ADVISORY BOARD; GILEAD: Speakers Bureau; JANSSEN: Other: ADVISORY BOARD, Speakers Bureau; ROCHE: Other: ADVISORY BOARD, Speakers Bureau; CELGENE: Other: ADVISORY BOARD, Speakers Bureau; AMGEN: Other: ADVISORY BOARD; ABBVIE: Other: ADVISORY BOARD, Speakers Bureau; INCYTE: Other: ADVISORY BOARD. Breccia:Pfizer: Honoraria; Novartis: Honoraria; BMS: Honoraria; Incyte: Honoraria.

scholarly journals Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

2019 ◽  
Vol 3 (1) ◽  
pp. 2514183X1882207 ◽  
Author(s):  
L Achtnichts ◽  
A Chan ◽  
A Czaplinski ◽  
T Derfuss ◽  
R Du Pasquier ◽  
...  
Keyword(s):  
Public Health ◽  
Multiple Sclerosis ◽  
Clinical Practice ◽  
Advisory Board ◽  
Daily Clinical Practice ◽  
European Medicines Agency ◽  
Scientific Advisory Board ◽  
Consensus Recommendations ◽  
Scientific Advisory ◽  
Disease Modifying

More than a dozen substances are meanwhile available for the disease-modifying immunotherapy of multiple sclerosis (MS). However, for some substances, there is a clear difference between approval in Switzerland (Swissmedic) and neighboring countries (European Medicines Agency (EMA)). In addition, limitations imposed by the Swiss Federal Office of Public Health in the specialties list (SL) have significant effects on use in daily clinical practice. In the following, we present consensus recommendations, which were reviewed and agreed upon by the Scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. We explicitly focus on practice-relevant differences in the approval of MS immunotherapies in Switzerland compared with the EMA area and discuss further limitations (SL) and their impact on the use in clinical practice. Immunotherapies with the same approval in Switzerland and the EMA area and symptomatic therapies are not discussed here.

Sign in / Sign up

Export Citation Format

Share Document